ClinicalTrials.gg
SuspendedNCT06228404Updated Nov 19, 2026

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

An Early Phase 1 interventional study of Enhanced autologous PSMA-CAR T in Metastatic Castration-resistant Prostate Cancer and Castration-resistant Prostate Cancer, sponsored by Shanghai Changzheng Hospital. Suspended at 1 site in China. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai Changzheng Hospital · Early Phase 1, Interventional, and Treatment

How we know

Why this study was suspended
The study is temporarily suspended to align with revised policy requirements.
Updated Nov 19, 2026Now SuspendedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
367th of 403
18 · median 90
Started
2024
with 44 others
Phase 1
93 of 487
47 open now
Registered
312th of 487
by date

Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 367th largest by planned enrollment of the 403 interventional ones that give a count, is one of 45 that started in 2024, is one of 93 in phase 1, and was the 312th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

219 more — sign in →

All 224 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration resistant prostate cancer, and the sample size is set to 7-18 subjects.

Read the detailed description

This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration resistant prostate cancer, and the sample size is set to 7-18 subjects. Based on the "3 + 3" dose escalation design principle, subjects will be divided into 3 groups from low dose to high dose in sequence (Group A; Group B; Group C). Additional subjects will be enrolled into the RP2D group to ensure that 6-9 efficacy-evaluable subjects are available in the RP2D group before entering the phase II study.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer
  • Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Castration-resistant Prostate Cancer
  • Metastasis
  • Prostate-Specific Membrane Antigen
  • Chimeric Antigen Receptor T cell
  • Refractory Castration-resistant Prostate Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understood and voluntarily signed for this study;
  2. male, aged 18-75 years;
  3. expected survival of more than 6 months;
  4. castration-resistant prostate adenocarcinoma (CRPC) patients.
  5. Receiving CRPC standard treatment (such as new endocrine therapy, chemotherapy and radium-223, etc., one or more of the combination therapy) after the diagnosis of CRPC, ineffective or progressive disease (PSA continued to rise for 3 months, or bone scan/whole-body MRI/PET-CT showed local recurrence or new metastatic lesions, demonstrating disease progression);
  6. PSMA expression in tumor cells was positive in immunohistochemical staining of prostate/metastatic tissue before enrollment;
  7. score \< 2 ;
  8. virological examination HAV (hepatitis A virus), (hepatitis B virus), (hepatitis C virus), (human immunodeficiency virus), TP (Treponema pallidum) quantitative detection was negative, (antigen and antibody screening method unknown, confirmed by nucleic acid method); hematological parameters met the following criteria: a. > 100 g/L; b. count > 100 × 109/L; c. neutrophils > 1.5 × 109/L.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria will be excluded:

  1. have received any previous treatment with CAR-T therapy ;
  2. have received any previous treatment that targets PSMA;
  3. tumor pathology suggests a special type of prostate cancer (e.g., neuroendocrine prostate cancer, etc.)
  4. severe mental disorders;
  5. suffered from previous , except for the following: a. basal cell carcinoma or squamous cell carcinoma after standardized treatment; b. having a primary malignancy, but completely resected, with a complete remission time of ≥ 5 years.
  6. Subjects with severe cardiovascular disease; a. (NYHA) stage III or IV congestive heart failure; b.Myocardial infarction ≤ 6 months prior to enrollment or coronary artery bypass graft (CABG); c. ventricular arrhythmia, or history of unexplained syncope, nonvasovagal or not due to dehydration; d.History of severe non-ischemic cardiomyopathy; e.Decreased (LVEF \< 55%) as assessed by echocardiogram or multigated acquisition (MUGA) scan, abnormal interventricular septal thickness and atrioventricular size associated with myocardial amyloidosis;
  7. active infectious disease or any major infectious event requiring high grade antibiotics;
  8. organ function in the following abnormalities: a. serum or alanine aminotransferase > 2.5ULN; CK > ; CK-MB > ULN; TnT > 1.5ULN; b. total > 1.5ULN; c. partial or activated partial thromboplastin time or international normalized ratio > 1.5ULN in the absence of anticoagulant therapy;
  9. participation in other clinical studies in the past three months or previous treatment with any gene therapy product;
  10. intolerance or to cyclophosphamide and fludarabine chemotherapy;
  11. unsuitability to participate in this clinical study in the opinion of the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Enhanced autologous PSMA-CAR T:

    Enhanced autologous PSMA-CAR T is an electrotransfer system based on non-viral transposons that integrates the CAR gene into the genome of host cells by electrotransfer using PMSA as a target, while this CAR vector co-expresses enhanced factors and plays a strong regulatory role in innate and adaptive immunity.

    Drug: Enhanced autologous PSMA-CAR T

Interventions

  • DrugEnhanced autologous PSMA-CAR T

    3 escalated dosing cohorts are designed to explore safety and efficacy of enhanced autologous PSMA-CAR T: cohort A: CART-PSMA cells 0.25×106/kgBW, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol; cohort B: CART-PSMA cells 0.75×106/kgBW,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol; cohort C: CART-PSMA cells 2×106/kgBW,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;

06

What researchers measure

Primary outcomes

  1. DLT

    The number and severity of dose-limiting toxicity (DLT) events

    Time frame: Within 28 Days After Enhanced autologous PSMA-CAR T Infusion

  2. The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE V5.0)

    Safety assessment: toxicity profile

    Time frame: Through 6 months after CAR-T cell infusion

  3. Cytokine Release Syndrome (CRS) grading post CAR T cell infusion

    Safety assessment: toxicity profile

    Time frame: Through 6 months after CAR-T cell infusion

Secondary outcomes

  1. Efficacy assessment: PSA changes

    Prostate-Specific Antigen (PSA) changes assessed by serum PSA measurement (ng/ml).

    Time frame: 6 months after CAR-T cell infusion

  2. Efficacy assessment: radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time between treatment with study drug and the development of imaging progression or death from any cause, whichever occurs first, with imaging progression encompassing the evaluation of progression of primary lesions, non-regional lymph node invasion, soft tissue metastases, and bone metastatic lesions according to RECIST 1.1 and PCWG3 criteria.

    Time frame: 3 months after CAR-T cell infusion

  3. Pharmacokinetics (PK) assessment: expansion of CAR-T cells

    With the day of the first infusion of the cellular preparation recorded as DO, the monitoring phase of the pharmacokinetic study started from 1 day before the first infusion (D-1). Expansion of CAR T cells will be assessed by concentration profile of CAR-T cells in peripheral blood after CAR-T infusion.

    Time frame: From Day 1 till at least 3 months after CAR-T cell infusion

  4. Pharmacokinetics (PK) assessment: persistence of CAR T cells

    With the day of the first infusion of the cellular preparation recorded as DO, the monitoring phase of the pharmacokinetic study started from 1 day before the first infusion (D-1). Persistence of CAR T cells will be assessed by T-cell survival time (area under the curve AUCO-28 at 28 days and area under the curve AUCO-90 at 90 days);

    Time frame: From Day 1 till at least 3 months after CAR-T cell infusion

  5. Pharmacodynamics (PD) assessment eg. (Level of IL-6)

    Pharmacokinetic (PD) endpoints is assessed by changes in serum cytokine levels (eg.IL-6) after CAR-T infusion.

    Time frame: From Day 1 till at least 3 months after CAR-T cell infusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 39 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2026 → Jun 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 29, 2024
StartActual
Mar 3, 2024
Primary completionEst.
Jun 2027was Aug 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Suspended The study is temporarily suspended to align with revised policy requirements.
changed Nov 19, 2026
Primary completion
Aug 2026→Jun 2027
Nov 19, 2026
Study completion
Dec 2026→Dec 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Active, not recruiting→Suspended
    Why stopped The study is temporarily suspended to align with revised policy requirements.
    Primary completion Aug 2026→Jun 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06228404
Collaborators
Bioray Laboratories
Responsible party
Ren Shancheng (Chief of Urology, Shanghai Changzheng Hospital) — Principal investigator
First posted
Jan 29, 2024
Start date
Mar 3, 2024
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion